2025
November 4th 2025–RevBio Receives First FDA Approval for a “Bone Glue” to treat Extremity Fractures in a Clinical Trial
October 6th 2025–RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE® to Treat Complex Spine Fractures
March 17th 2025–RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product
January 30th 2025–RevBio Issued a Key Patent for its Regenerative Bone Adhesive Technology by the United States Patent and Trademark Office
2024
December 11th 2024–RevBio Receives Both FDA Approval to Expand its Clinical Trial and CMS Reimbursement for its Regenerative Bone Adhesive for Cranial Flap Fixation
September 18th 2024–RevBio Receives a $2.4 Million NIH Grant to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation and Enrolls First Five Patients
2023
December 8th 2023–RevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation
October 25th 2023–RevBio Awarded a $2 Million Follow-On NIH Grant to Reduce Opioid Use and Addiction with TETRANITE®
October 6th 2023–RevBio Awarded a $3.4 Million NIH Grant for Its Novel Regenerative Bone Adhesive to Treat Complex Fractures
August 1st 2023–RevBio Receives FDA Approval to Conduct its Second U.S.-Based Clinical Trial for Dental Implant Stabilization
June 7th 2023–RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product
May 22nd 2023–RevBio Receives ISO Certification for its Quality Management Systems
February 14th 2023–RevBio Receives a Strategic Investment from Pacific Dental Services to Support Ongoing Clinical Trials in Implant Dentistry
January 18th 2023–RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial
2022
December 15th 2022–A Lowell Biotech will test its ‘bone glue’ in space, Boston Business Journal Article
December 9th 2022–RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station
November 15th 2022–Novel Bone Adhesive to Fly on SpaceX CRS-26
September 20th 2022–RevBio Receives NIH Grant to Explore the Treatment of Vertebral Compression Fractures with Its Regenerative Bone Adhesive Technology
September 15th 2022–RevBio Receives Approval from the U.K.’s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial
2021
October 25th 2021–BONEZONE: RevBio Looked Below the Ocean to Find a Way to Treat Bone Fractures
April 6th 2021–RevBio Receives a $2 Million NIH Grant to Pursue the Treatment of Wrist Fractures with Its Innovative Bone Adhesive Technology
March 9th 2021–RevBio Awarded Funding to Conduct an In Vivo Bone Experiment on the International Space Station
February 4th 2021–RevBio Enters the Animal Health Market to Help Improve Canine Dental Care
2020
August 4th 2020–RevBio (Formerly LaunchPad Medical) Rebrands as RevBio and Launches an Updated Website
July 7th 2020–RevBio (Formerly LaunchPad Medical) Initiates its First European Clinical Study
June 2nd 2020–RevBio (Formerly LaunchPad Medical) Wins a Coveted $1.8 Million Michigan-Pittsburgh-Wyss Regenerative Medicine Center Grant
May 5th 2020–RevBio (Formerly LaunchPad Medical) Wins a $2.5 Million NIH Grant to Improve Cranial Procedures
2019
December 19th 2019–RevBio (Formerly LaunchPad Medical) Accelerates Enrollment in its First-In-Man Clinical Study
November 6th 2019–RevBio (Formerly LaunchPad Medical) Wins NIH HEAL Grant to Reduce Opioid Use and Addiction
September 12th 2019–RevBio (Formerly LaunchPad Medical) Received FDA Approval to Initiate a Clinical Study
2015
June 3rd 2015–FIERCE BIOTECH: Former Stryker R&D Exec Spins off New Company with Novel Bone Adhesive
June 1st 2015–RevBio (Formerly LaunchPad Medical) Executives Definitive License Agreement with Stryker for Novel Bone Adhesive Technology